Condition
Neurocognitive
Total Trials
3
Recruiting
0
Active
0
Completed
2
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 17/100
Termination Rate
0.0%
0 terminated out of 3 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
33%
1 trials in Phase 3/4
Results Transparency
50%
1 of 2 completed with results
Key Signals
1 with results100% success
Data Visualizations
Phase Distribution
3Total
Not Applicable (1)
P 2 (1)
P 3 (1)
Trial Status
Completed2
Unknown1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (3)
Showing 3 of 3 trials
NCT03169881Phase 3CompletedPrimary
Darbepoetin Trial to Improve Red Cell Mass and Neuroprotection in Preterm Infants
NCT07004114Not ApplicableCompleted
Effects of Neurocognitive Training on Chronic Ankle Instability
NCT04829019Phase 2UnknownPrimary
Neurocognition in NSCLC Patients Treated With Osimertinib or Osimertinib + WBI
Showing all 3 trials